Scope
NICE guideline NG148 covers preventing, detecting and managing acute kidney injury (AKI) in adults, children and young people. Its recommendations carry dates from 2013 to 2024, and the 2024-dated recommendations deal with assessing adults before iodine-based contrast media. The guideline covers risk assessment in acute illness, before contrast and before surgery. It also addresses in-hospital monitoring and prevention, and the detection criteria for AKI. Further topics are investigating the cause with urine dipstick testing and urinary tract ultrasound, and relieving urological obstruction. It covers drug management, referral for renal replacement therapy, nephrology referral and follow-up, and information for patients and carers.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognising risk and suspecting AKI
- For acutely ill adults, check serum creatinine against baseline when risk factors are likely or present. Examples include CKD (particular risk with eGFR less than 60 ml/min/1.73 m2), oliguria below 0.5 ml/kg/hour, iodine-based contrast within the past week, deteriorating early warning scores and age 65 years or over. [1]
- In acutely ill children and young people, investigate with creatinine compared with baseline when risk factors are present. Paediatric-specific factors include severe diarrhoea (bloody diarrhoea carries particular risk), nephritis signs such as oedema or haematuria, haematological malignancy and hypotension. [1]
- In people with CKD and no obvious acute illness, a creatinine rise may reflect AKI rather than worsening chronic disease. When an adult, child or young person presents with an illness that has no clear acute component, ensure AKI is considered if any of the following applies. These are CKD (especially stage 3B, 4 or 5) or urological disease, new or significantly worsening urological symptoms, and symptoms suggesting AKI complications. Features of multi-system disease affecting the kidneys and other organs, such as AKI with a purpuric rash, also apply. [1]
- Assess AKI risk in adults before surgery. Examples of factors the guideline links to higher risk are emergency surgery (especially with sepsis or hypovolaemia), intraperitoneal surgery, CKD (particular risk with eGFR less than 60 ml/min/1.73 m2) and age 65 years or over. Perioperative use of drugs that can cause or worsen kidney injury, particularly NSAIDs after surgery, is another example; the full list includes further factors. Use the assessment to shape the management plan, and include AKI in the routine risk–benefit discussion. [1]
Iodine-based contrast media in adults
- Discuss the benefits and risks of contrast-based tests or treatments with the person, and with family or carers where appropriate. Be aware that eGFR less than 30 ml/min/1.73 m2 carries a small but increased AKI risk. In an emergency, do not delay contrast if delay is likely to be clinically significant. [1]
- Before requesting a non-urgent contrast CT, assess for pre-existing kidney disease. Where available, use an eGFR from the past 6 months. Consider a more recent value if the person has been acutely unwell or clinically unstable since that test. [1]
- If no eGFR from the past 6 months exists, ask screening questions. These cover kidney disease or transplant, kidney specialist or urology involvement, and symptoms of acute illness likely to cause AKI, such as diarrhoea, vomiting, fever, hypovolaemia, infection or difficulty passing urine. If answers suggest kidney disease or likely AKI, consider an eGFR test. If there is no kidney disease history and the person is clinically stable, consider proceeding without further pre-scan bloods. [1]
- Encourage oral hydration before and after intravenous contrast procedures in adults at increased risk of contrast-associated AKI. [1]
- For inpatients at particularly high risk, consider intravenous volume expansion with isotonic sodium bicarbonate or 0.9% sodium chloride. Examples of high risk are eGFR less than 30 ml/min/1.73 m2, renal transplant, large contrast volume (above standard diagnostic dose or repeat dosing within 24 hours) and intra-arterial contrast with first-pass renal exposure. [1]
- Consider temporarily stopping ACE inhibitors and ARBs in adults with CKD and eGFR less than 30 ml/min/1.73 m2 who are having contrast. For adults on renal replacement therapy, including transplant recipients, discuss care with nephrology before offering contrast. This discussion should not delay emergency imaging. [1]
Monitoring and prevention in hospital
- Follow the NICE guideline on acutely ill adults in hospital on using track and trigger early warning systems to identify adults whose deterioration puts them at risk of AKI. Ensure oliguria (below 0.5 ml/kg/hour) is recognised and acted on if the score does not include urine output. [1]
- Consider a paediatric early warning score for admitted children and young people, and observe more often when physiology is abnormal. For those at risk because of the acute-illness risk factors listed earlier in the guideline, measure urine output and weigh twice daily for fluid balance. Measure urea, creatinine and electrolytes, and think about lactate, glucose and blood gases. [1]
- Consider electronic clinical decision support without letting it replace clinical judgement. Seek pharmacist advice on medicines and dosing in people with or at risk of AKI. Consider temporarily stopping ACE inhibitors and ARBs during diarrhoea, vomiting or sepsis until the person has improved and stabilised. [1]
Detection and identifying the cause
- In line with (p)RIFLE, AKIN or KDIGO definitions, AKI is detected by any one of the following. A serum creatinine rise of 26 micromol/litre or more within 48 hours. A serum creatinine rise of 50% or more known or presumed within the past 7 days. Urine output below 0.5 ml/kg/hour for over 6 hours in adults, or over 8 hours in children and young people. In children and young people, an eGFR fall of 25% or more within the past 7 days. [1]
- Monitor creatinine regularly in anyone with or at risk of AKI. Frequency depends on clinical need, and daily testing is typical in hospital. [1]
- Identify and document the cause of AKI. Dipstick urine for blood, protein, leucocytes, nitrites and glucose as soon as AKI is suspected or detected, and act on abnormal results. Haematuria with proteinuria and no obvious cause should prompt thought of acute nephritis and nephrology referral, provided UTI and catheter trauma are absent. [1]
- Do not routinely offer urinary tract ultrasound once the cause is known. Offer immediate ultrasound, within 6 hours of assessment, if pyonephrosis is suspected. Offer urgent ultrasound, within 24 hours, if no cause is identified or there is a risk of obstruction. [1]
Management and referral
- Refer all upper tract obstruction to urology. Refer immediately for pyonephrosis, an obstructed solitary kidney, bilateral obstruction or obstruction-related AKI complications. If nephrostomy or stenting is used, perform it as soon as possible and within 12 hours of diagnosis. [1]
- Loop diuretics are not routine AKI treatment. They may be considered for fluid overload or oedema while awaiting renal replacement therapy, or during recovery in people not on it. Do not offer low-dose dopamine. [1]
- Discuss possible renal replacement therapy indications immediately with nephrology and/or critical care. Refer immediately when hyperkalaemia, metabolic acidosis, uraemic symptoms or complications, fluid overload or pulmonary oedema fail medical management. [1]
- Judge whether to start renal replacement therapy on the whole clinical picture, not isolated urea, creatinine or potassium values. With significant comorbidities, discuss likely benefit with the patient or their parent or carer and within the multidisciplinary team. [1]
- Discuss management with nephrology as soon as possible and within 24 hours of detection in several situations. These are a possible diagnosis needing specialist treatment (such as vasculitis, glomerulonephritis, tubulointerstitial nephritis or myeloma), unclear cause or inadequate response, complications, stage 3 AKI, renal transplant, or CKD stage 4 or 5. [1]
- Do not refer to nephrology when the cause is clear and AKI is responding promptly, unless the person has a renal transplant. In intensive care, refer to nephrology when the cause is uncertain or specialist kidney management may be needed. For a person with severe illness who might benefit from treatment but where it is uncertain whether they are nearing the end of life, consider discussing management with nephrology. [1]
- After AKI, monitor creatinine at a frequency guided by renal function and stability at discharge. Consider nephrology referral if eGFR is 30 ml/min/1.73 m2 or less after recovery. Consider paediatric nephrology referral for recovered children with hypertension, impaired function or 1+ or greater proteinuria on early morning urine dipstick. [1]
Information for patients and carers
- Discuss treatment, monitoring, prognosis and support early. Provide information on long-term treatment options, monitoring, self-management and support with an appropriate multidisciplinary team. People needing renal replacement therapy after discharge should be given information on future care, including dialysis session frequency and length, and preparation such as a fistula or peritoneal catheter. [1]
- Talk with at-risk people about AKI risk from dehydrating illness and from nephrotoxic drugs, including over-the-counter NSAIDs. This applies particularly to those with CKD and eGFR less than 60 ml/min/1.73 m2, or with impairment limiting their access to fluids. Involve carers where appropriate. [1]
Limitations and use
- Recommendations 1.1.5–1.1.12 and 1.2.7–1.2.10 on iodine-based contrast media apply to adults only.
- Several recommendations defer to other NICE guidelines (acutely ill adults in hospital, intravenous fluid therapy in adults, shared decision making), and those guidelines are not summarised here.
- Research recommendations, rationale and impact sections, and the evidence reviews were not part of the reviewed source.
- Linked visual algorithms, including the NHS England AKI early identification algorithm, were not reviewed.
- Most recommendations date from 2013. The contrast-related risk assessment recommendations are dated 2024, the contrast prevention recommendations are mostly dated 2019, and one recommendation is dated 2013, amended 2024.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute kidney injury: prevention, detection and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 18 December 2019
- Publisher’s latest update
- 16 October 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.